Lv4
470 积分 2024-07-10 加入
Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China
4天前
已完结
Cost effectiveness of innovative anti-cancer drugs and reimbursement decisions in China
15天前
已完结
Cost effectiveness of innovative anti-cancer drugs and reimbursement decisions in China
1个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
2个月前
已完结
Gestational Hypertension and Preeclampsia
3个月前
已完结
A systematic review of eczematous eruptions in patients receiving biologic therapy
5个月前
已完结
Health state utilities in non–small cell lung cancer: An international study
5个月前
已完结
Utilities and disutilities for attributes of injectable treatments for type 2 diabetes
5个月前
已完结
CKD in China: Evolving Spectrum and Public Health Implications
6个月前
已完结
The cost of Hypertensive Disorders of Pregnancy to the Australian healthcare system
7个月前
已关闭
皖公网安备34019202002308
